The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

A new study reported that Novo Nordisk spent $7.5 million over 2 years on more than 15,000 internet keywords — many focused ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

Shares of Novo Nordisk plunged after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's ...

They also follow a recent partnership with Costco, which began offering low-dose Ozempic and Wegovy for $499 per month out of ...

Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.

The maker of the weight loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of the blockbuster ...